VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015

Sep 9, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-09-04

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-09-04	Common Stock	M	9063	$53.74	Acquired	136578	Direct
2015-09-04	Common Stock	S	400	$124.43	Disposed	136178	Direct
2015-09-04	Common Stock	S	5200	$125.42	Disposed	130978	Direct
2015-09-04	Common Stock	S	3463	$126.44	Disposed	127515	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-09-04	Stock Option (right to buy)	$53.74	M	9063	Disposed	2022-09-03	Common Stock (9063)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $124.43 (range $123.98 to $124.85).

F4: Open market sales reported on this line occurred at a weighted average price of $125.42 (range $124.99 to $125.98).

F5: Open market sales reported on this line occurred at a weighted average price of $126.44 (range $126.00 to $126.92).

F6: The option vests in 16 quarterly installments from 09/04/2012.